Abstract-Extracellular superoxide dismutase (SOD3) is a secretory copper enzyme involved in protecting angiotensin II (Ang II)-induced hypertension. We found previously that Ang II upregulates SOD3 expression and activity as a counterregulatory mechanism; however, underlying mechanisms are unclear. Antioxidant 1 (Atox1) is shown to act as a copper-dependent transcription factor, as well as a copper chaperone, for SOD3 in vitro, but its role in Ang II-induced hypertension in vivo is unknown. Here we show that Ang II infusion increases Atox1 expression, as well as SOD3 expression and activity, in aortas of wild-type mice, which are inhibited in mice lacking Atox1. Accordingly, Ang II increases vascular superoxide production, reduces endothelium-dependent vasodilation, and increases vasoconstriction in mesenteric arteries to a greater extent in Atox1 Ϫ/Ϫ than in wild-type mice. This contributes to augmented hypertensive response to Ang II in Atox1 Ϫ/Ϫ mice. In cultured vascular smooth muscle cells, Ang II promotes translocation of Atox1 to the nucleus, thereby increasing SOD3 transcription by binding to Atox1-responsive element in the SOD3 promoter. Furthermore, Ang II increases Atox1 binding to the copper exporter ATP7A, which obtains copper from Atox1, as well as translocation of ATP7A to plasma membranes, where it colocalizes with SOD3. As its consequence, Ang II decreases vascular copper levels, which is inhibited in Atox1 Ϫ/Ϫ mice. In summary, Atox1 functions to prevent Ang II-induced endothelial dysfunction and hypercontraction in resistant vessels, as well as hypertension, in vivo by reducing extracellular superoxide levels via increasing vascular SOD3 expression and activity. (Hypertension. 2012;60:00-00.) • Online Data Supplement Key Words: angiotensin II Ⅲ hypertension Ⅲ oxidative stress Ⅲ antioxidant 1 Ⅲ SOD3 Ⅲ SOD1 Ⅲ copper A ngiotensin II (Ang II), the principal effector peptide of the renin-angiotensin system, plays a major role in the initiation and progression of vascular diseases, such as hypertension, in part through reactive oxygen species.
A ngiotensin II (Ang II), the principal effector peptide of the renin-angiotensin system, plays a major role in the initiation and progression of vascular diseases, such as hypertension, in part through reactive oxygen species. 1 Ang II-induced increase in reactive oxygen species in particular, superoxide (O 2 ·Ϫ ), leads to decreased bioavailability of NO, which impairs endothelium-dependent vasodilatation and promotes vasoconstriction. A major antioxidant defense system against O 2 ·Ϫ is the superoxide dismutases (SODs): the cytoplasmic Cu/ZnSOD (SOD1), the mitochondrial MnSOD, and the extracellular Cu/ZnSOD (SOD3).
2 SOD3 is a major extracellular antioxidant enzyme highly expressed in the vasculature, and it plays an important role in regulating blood pressure and endothelial function by reducing extracellular O 2 ·Ϫ level, thereby preventing oxidative inactivation of NO released from endothelium. [3] [4] [5] We and others reported that Ang II-induced increase in blood pressure, vascular O 2 ·Ϫ levels, and endothelial dysfunction is augmented in SOD3 Ϫ/Ϫ mice, 4, 5 which are ameliorated by treatment with recombinant SOD3. 4 We have also shown that Ang II increases expression and activity of SOD3 in vitro and in vivo. 6 These findings suggest that Ang II-induced modulation of SOD3 is an important protective mechanism that prevents overproduction of O 2 ·Ϫ ; however, underlying regulatory mechanisms remain unknown.
Copper is an essential micronutrient by serving as a cofactor for key metabolic and redox-related proteins, and SOD1 and SOD3 require catalytic copper for their full enzymatic activity. 2 Under physiological conditions, the intracellular level of free copper is extraordinarily restricted. 7 Thus, soluble copper carrier proteins, termed "copper chaperones," are required to directly transfer copper to specific cellular target proteins. SOD1 obtains copper through interaction with the cytosolic copper chaperone for SOD1. 8 Using cultured fibroblasts, we demonstrated that exogenous copperinduced full activation of SOD3 requires copper chaperone antioxidant 1 (Atox1), which delivers copper to the secretory copper enzymes, likely via interaction with the copper exporter ATP7A (Menkes ATPase). [9] [10] [11] Of note, the Atox1-ATP7A pathway is involved not only to activate secretory copper enzyme but also to control intracellular copper levels by regulating secretion of excess copper. Recently, we have shown that Atox1 also serves as a transcription factor for copper-induced increase in SOD3 and cyclin D1 expression in vitro. 9, 12 The association of copper homeostasis with hypertension has been reported. 13 Tissue levels of copper are either decreased or increased in hypertensive rats, which have been proposed to be affected by severity of hypertension. 14, 15 Serum copper concentration is increased in humans characterized by either essential or pulmonary hypertension, 16, 17 as well as various rodent hypertension models.
14 Copperdeficient diet alters blood pressure in an age-dependent manner. 18, 19 However, the role of Atox1 in hypertension in vivo has not been investigated.
We performed the present study to test the hypothesis that Atox1 may play a critical role in modulating blood pressure and vascular function in resistance vessels via regulating vascular SOD3 during Ang II-induced hypertension. Here we demonstrate that Ang II infusion markedly increases Atox1 protein expression, as well as SOD3 expression, and specific activity in aortas from wild-type (WT) mice, which are inhibited in Atox1 Ϫ/Ϫ mice. Ang II increases vascular O 2 ·Ϫ production and promotes endothelial dysfunction in mesenteric arteries to a greater extent in Atox1 Ϫ/Ϫ than in WT mice. This contributes to the exaggerated hypertensive response to Ang II in Atox1
Ϫ/Ϫ mice. Mechanistically, Ang II increases Atox1 binding to the SOD3 promoter to increase SOD3 transcription, as well as Atox1 binding to copper exporter ATP7A, to increase specific activity of SOD3 in cultured vascular smooth muscle cells (VSMCs). Thus, Ang IIinduced upregulation of Atox1 may represent an important counterregulatory mechanism that blunts overproduction of O 2 ·Ϫ or elevating blood pressure through regulating SOD3 expression and activity in the vasculature.
Materials and Methods

Animal and Cell Culture Studies
Atox1
Ϫ/Ϫ mice (backcrossed 8 times to C57Bl/6) were obtained from Mutant Mouse Regional Resource Centers. Atox1 Ϫ/Ϫ mice were originally reported to have phenotypes that show perinatal death (45% of pups) or survive Ͼ1 month. 20 Our laboratory further backcrossed Atox1 Ϫ/Ϫ mice to C57Bl/6 mice Ͼ10 times and, thus, used C57Bl/6 mice as a control. "Survivor" mice were intercrossed Ͼ10 times, and Atox1 Ϫ/Ϫ mice used in the present study survived Ͼ6 months (90%). For in vivo experiments, we performed Ang II infusion by osmotic minipumps, blood pressure measurement by the tail-cuff method, immunohistochemical and Western analysis, realtime PCR, SOD activity assay, vascular O 2 ·Ϫ production, vascular reactivity studies by wire myograph, copper measurements by inductively coupled plasma mass spectrometry, and synchrotron x-ray fluorescence microscopy analysis. All of the studies were approved by the animal care and use committee of the University of Illinois-Chicago. For in vitro experiments, rat VSMCs (between passage 7 and 15) were maintained in DMEM supplemented with 10% bovine serum. Using them, we performed nuclear/cytoplasmic fractionation, immunofluorescence, plasmid constructs, transient transfection and reporter assay, and DNA pull-down assay.
An expanded Materials and Methods section is available in the online-only Data Supplement.
Results
Atox1 Expression Is Increased in Aortas of Ang II-Infused Mice
We first examined the Atox1 expression in aortas from mice with Ang II-induced hypertension. Western ( Figure 1A ) and immunohistochemical ( Figure 1B ) analysis showed that Ang II infusion (0.7 mg/kg per day) for 7 days significantly increased Atox1 protein expression in the medial layer of the aorta. Importantly, some Atox1-positive cells were found in the nucleus ( Figure 1B ).
Effect of Ang II Infusion on SOD3 Expression and Activity in Aortas of WT and Atox1
؊/؊ Mice Atox1 has been shown to function as a copper chaperone for secretory copper-containing enzymes 20, 21 and a copperdependent transcription factor in vitro. 9, 10, 12 Thus, we examined the SOD3 expression and activity in aortas of Ang II-infused Atox1
Ϫ/Ϫ mice. The body weights and various organ weights (heart, kidney, lung, and brain) were not different between C57Bl/6 WT and Atox1 Ϫ/Ϫ mice ( Figure  S1 , available in the online-only Data Supplement). Ang II infusion for 7 days significantly increased mRNA and protein levels ( Figure 2A and 2B) , as well as activity of SOD3 ( Figure 2C ), but not those of SOD1, in aortas from WT mice. These Ang II-induced effects were almost completely inhibited in Atox1 Ϫ/Ϫ mice (Figure 2 ). At baseline, SOD3 protein and mRNA levels, as well as activity, were decreased in Atox1 Ϫ/Ϫ compared with WT aortas. In contrast, total SOD activity and protein expression of other major Cu enzymes (including ceruloplasmin or lysyl oxidase) in aortas were similar between WT and Atox1 Ϫ/Ϫ mice at baseline and after 
Effect of Ang II on Mesenteric Vascular Function in WT Mice and Atox1 ؊/؊ Mice
To determine the role of Atox1 in endothelium-dependent vasodilation, we used mesenteric arteries (200 m in diameter) with the wire myograph approach. Under basal conditions, endothelium-dependent relaxations to acetylcholine were impaired in Atox1 Ϫ/Ϫ mice compared with those of WT mice ( Figure 4A , left). Ang II caused a marked impairment of acetylcholine-evoked relaxation to a greater extent in arteries of Atox1 Ϫ/Ϫ than WT mice (max relaxation, 44.8Ϯ1.72% versus 61.3Ϯ3.02%; PϽ0.01). Relaxations to endotheliumindependent vasodilator sodium nitroprusside were similar in WT and Atox1 Ϫ/Ϫ mice at baseline and were not altered by 
Ang II (Figure 4B). The impairment of acetylcholine-induced vasorelaxation in Ang II-infused Atox1
Ϫ/Ϫ mice and WT mice was rescued by coinfusion of the SOD mimetic Tempol ( Figure 4A, right) . In mice without Ang II infusion, direct contractile responses to Ang II were markedly increased in mesenteric arteries of Atox1 Ϫ/Ϫ mice compared with WT mice, which was rescued by the SOD mimetic Tempol ( Figure S4 ). By contrast, contractions induced by phenylephrine, which did not produce O 2 ·Ϫ , or KCl were not different in WT and Atox1 Ϫ/Ϫ mice. Thus, non-KCl normalized data for Ang II-induced vasoconstriction in WT and Atox1 Ϫ/Ϫ mice was similar to that after normalization (data not shown). Thus, these results suggest that Atox1 is required for full activity of SOD3, thus decreasing O 2 ·Ϫ level, thereby inhibiting Ang II-induced endothelial dysfunction and vasoconstriction.
Ang II Promotes Translocation of Atox1 Into the Nucleus in VSMCs
To examine the molecular mechanisms by which Atox1 regulates SOD3 expression and activity in the vasculature, we next examined the subcellular localization of Atox1. Immunofluorescence analysis in VSMCs shows that Ang II stimulation promoted translocation of Atox1 from the cytosol to the nucleus in a time-dependent manner with peak at 30 minutes ( Figure 5A ). Consistently, subcellular fractionation showed that Atox1 protein level is increased in nuclear fraction, with a peak at 30 minutes after Ang II stimulation, and then decreased after 120 minutes ( Figure 5B) . We confirmed the purity of nuclear and cytosolic fractions by detecting the markers, laminin B and tubulin, respectively.
Ang II Stimulates Atox1 Binding to the SOD3 Promoter and Its Promoter Activity in VSMCs
To determine whether Atox1 functions as a transcription factor for SOD3 in Ang II-stimulated VSMCs, we performed luciferase reporter gene assays. Ang II stimulation increased SOD3 promoter activity, which was blocked by the mutation of Atox1 responsive elements 12 in the SOD3 promoter ( Figure 6A ). DNA pull-down assays show that Atox1 directly bound to the Atox1 responsive element, including the DNA segment ( Figure 6B ). These results suggest that Ang II Atox1 also functions to deliver copper to secretory copper enzymes via interaction with copper exporter ATP7A in yeast system. 21, 22 Coimmunoprecipitation assay reveals that Ang II increased Atox1 binding to ATP7A (Figure 7A ), as well as ATP7A binding to the secretory copper enzyme SOD3 ( Figure 7B ), in a time-dependent manner. This Ang IIinduced formation of the Atox1/ATP7A/SOD3 complex may be required for increasing SOD3-specific activity. To gain further insights for the mechanism by which Atox1 increases SOD3 specific activity, we examined the subcellular localization of ATP7A in response to Ang II in VSMCs. Immunofluorescence analysis shows that Ang II stimulation promoted the translocation of ATP7A from trans-Golgi network to plasma membrane and post-Golgi vesicles, where it colocalized with SOD3. This Ang II-induced alternation of ATP7A localization was inhibited by Atox1 small interfering RNA ( Figure 7C and 7D) .
Effect of Ang II on Vascular Copper Levels in WT Mice and Atox1
؊/؊ Mice Because copper exporter ATP7A is involved in delivering copper to the SOD3, which is secreted to the extracellular space, we examined the copper levels in aortas from WT and Atox1 Ϫ/Ϫ mice with or without Ang II infusion. Inductively coupled plasma mass spectrometry ( Figure 8A ) and synchrotron-based x-ray fluorescence microscopy analysis ( Figure 8B) show that Ang II infusion significantly decreased copper levels in the medial layers of the aorta. Specific decrease in copper levels was normalized by sulfur levels, which was used as a surrogate for total cellular protein and to visualize the morphology of tissue sections. 23 By contrast,
Atox1
Ϫ/Ϫ mice showed increased copper levels in the aorta at basal state, which was not affected by Ang II infusion ( Figure  8A and 8B).
Discussion
Previous studies have implicated a protective role for intracellular SOD1, as well as extracellular SOD3, in limiting endothelial dysfunction produced by Ang II. 4, 5, 24 In the present study, we demonstrate that Ang II infusion increases Atox1 expression in aortas of WT mice. Activity and expression of SOD3 but not those of SOD1 are decreased in Atox1 Ϫ/Ϫ mice treated with Ang II. This leads to exaggerated Ang II-induced vascular O 2 ·Ϫ production, thereby promoting Ang II-induced endothelial dysfunction and vasoconstriction, which, in turn, augments systolic blood pressure in Atox1 Ϫ/Ϫ mice. These changes induced by Atox1 deficiency are rescued by adding the SOD mimetic Tempol. Thus, Atox1 functions to prevent Ang II-induced endothelial dysfunction and hypertension by reducing O 2 ·Ϫ levels via increasing vascular SOD3 expression and activity. Moreover, Atox1 regulates copper levels in the vasculature during Ang II-induced hypertension.
Impairment of endothelium-dependent acetylcholineinduced relaxation in mesenteric arteries from Ang II-infused Atox1 Ϫ/Ϫ mice is likely attributed to a decrease in endothelial NO · bioavailability, because endothelium-independent vasodilation is not affected by Ang II in Atox1 Ϫ/Ϫ mice. There is significant reduction in vascular reactivity in vehicle-infused Atox1 Ϫ/Ϫ mice, which may be in part because of the slight but not significant increase in O 2 ·Ϫ levels in these mice at baseline. However, Ang II-induced hypertension but not basal blood pressure is significantly altered in Atox1 Ϫ/Ϫ mice. In addition, it has been reported that Ang II increases vasoconstriction partially through O 2 ·Ϫ -induced inactivation of vasorelaxant NO, 1 although this response depends on vascular bed and genetic background. 25, 26 In the present study, we found that contractions to the Ang II but not KCl are significantly increased in mesenteric arteries of the Atox1 Ϫ/Ϫ mice compared with WT mice. This is inhibited by the SOD mimetic Tempol. Thus, the loss of NO bioavailability induced by decrease in SOD3 activity and subsequent increase in O 2 ·Ϫ levels in Atox1-deficient arteries may contribute not only to impaired endothelium-dependent vasodilation but also to enhanced Ang II-induced vasoconstriction. This, in turn, likely increases systemic vascular resistance in Atox1 Ϫ/Ϫ mice during Ang II infusion and, thus, augments the hypertensive response observed in these animals. Of note, it has been shown that endothelium-dependent vasorelaxation in mesenteric arteries depends on not only NO but also epoxyeicosatrienoic acids and H 2 O 2 , which have been proposed as endothelium-dependent hyperpolarizing factor. 27 Thus, Atox-1 Ϫ/Ϫ mice have increased vascular O 2 ·Ϫ , which would scavenge NO but also may have reduced vascular H 2 O 2 to inhibit action of endothelium-dependent hyperpolarizing factors. This point requires further investigation in future study.
We found that the levels of total SOD activity were similar between WT and Atox1 Ϫ/Ϫ mice and were not changed by Ang II infusion. This result may reflect the fact that SOD1 activity, which consists of more than half of total SOD activity, is not dependent on Atox1. Nevertheless, the dramatic decrease in SOD3 activity by Atox1 deficiency likely has a major impact on increasing O 2 ·Ϫ levels in the interstitial space, where this enzyme is localized. This will efficiently promote oxidative inactivation of NO, which traverses from the endothelial cells to VSMCs, thereby preventing endothelium-dependent vasorelaxation, which, in turn, increases blood pressure in Atox1 Ϫ/Ϫ mice, as reported for SOD3 Ϫ/Ϫ mice. 2 Of note, endothelial dysfunction in the coronary circulation of humans has profound prognostic implications in that it predicts adverse cardiovascular events and long-term outcome. 28 The R213G polymorphism in the SOD3 gene, which reduces binding to the endothelial surface and increases serum SOD3 levels, 3 has been linked to an increase in cardiovascular risk. 29 Thus, the protective role of Atox1 in endothelial function through SOD3 would have potential clinical impact.
In this study, SOD3 protein and mRNA expression, as well as nuclear Atox1 expression in blood vessels, are increased by Ang II infusion, which is abolished in Atox1 Ϫ/Ϫ mice. Consistent with our results, Hamza et al 30 originally showed that Atox1 is localized in the nucleus in cultured cells; however, functional significance of nuclear Atox1 was not addressed. Using promoter analysis and DNA pull-down assay in cultured VSMCs, we demonstrate that Ang II stimulation promotes translocation of Atox1 from the cytosol to the nucleus, as well as Atox1 binding to the Atox1 response element in the SOD3 promoter. This observation is consistent with our earlier study that Atox1 serves as a transcription factor for copper-induced increase in SOD3 and cyclin D1 expression in fibroblasts. 9, 12 The present study also found that expression of other coppercontaining enzymes, including lysyl oxidase, ceruloplasmin, or SOD1, was not changed in Atox1 Ϫ/Ϫ arteries as compared with WT with or without Ang II infusion. This is consistent with the fact that SOD3 but not lysyl oxidase, ceruloplasmin, or SOD1 has Atox1-responsive elements in its promoters. Thus, the current study provides the first evidence that "agonist-induced" transcription factor function of Atox1 for SOD3 plays a potentially important role in Ang II-induced upregulation of SOD3 expression in blood vessels, thereby modulating O 2 ·Ϫ levels and hypertensive responses induced by Ang II (Figure 9 ).
Copper chaperone function of Atox1 to deliver copper to SOD3 in Ang II-treated VSMCs is also demonstrated in this study. We found that Ang II promotes Atox1 binding to the copper exporter ATP7A, which obtains copper from Atox1. It also stimulates ATP7A translocation from transGolgi network to plasma membrane, where it colocalizes with SOD3. Consistent with our results, Atox1 is shown to deliver copper to secretory copper enzymes via interaction with ATP7A in yeast. 21, 22 Furthermore, ATP7A is reported to deliver copper to the secretory copper enzymes in the post-Golgi vesicles rather than in trans-Golgi network, where copper loading normally takes place. 31, 32 We reported previously that Ang II infusion-induced increase in blood pressure and vascular O 2 ·Ϫ production are augmented in ATP7A mutant mice because of a decrease in SOD3 activity. 33 In line with this, the present study provides the additional new evidence that Ang II promotes copper chaperone function of Atox1 by facilitating formation of the Atox1/ATP7A/SOD3 complex, thereby increasing specific SOD3 activity ( Figure 9 ).
The association of copper metabolism with hypertension has been implicated. 13 However, there is no information regarding vascular copper levels in hypertension or involvement of Atox1 in this response. The present study shows that Ang II treatment significantly decreases vascular copper levels, as assessed by inductively coupled plasma mass spectrometry and synchrotron-based x-ray fluorescence microscopy analysis, which is inhibited in Atox1 Ϫ/Ϫ mice. This might in part reflect the Ang IIstimulated secretion of copper-loaded SOD3 to the circu- lation via the Atox1-ATP7A pathway, despite the fact that the majority of SOD3 will bind to the extracellular matrix. In addition, Ang II-induced decrease in vascular copper levels may be also because of secretion of secretory copper-containing proteins or excess copper to protect cells from its toxicity. This is consistent with a previous study that showed that levels of copper in some tissues, such as liver and kidney, are significantly lower in hypertensive rodents. 14 The physiological consequence of copper export via ATP7A is placental copper transport to the developing fetus during pregnancy or providing copper as part of a neuronal protective mechanism. 34 Thus, the present study provides the first evidence that vascular copper levels are altered during Ang II-induced hypertension, which is at least in part regulated by Atox1. Detailed analysis of molecular mechanism and functional significance of altered copper levels in hypertension requires future investigation.
Previous studies have shown that SOD3 Ϫ/Ϫ mice have normal blood pressure at baseline, but Ang II-induced increase in blood pressure is augmented in these mice in a time-dependent manner with a peak at day 7, which remained elevated at least until day 14.
5 Consistent with this, the present study found that Atox1 Ϫ/Ϫ mice showed similar time course of exaggerated hypertensive response to Ang II, as reported for SOD3 Ϫ/Ϫ mice. It has been reported that deletion of SOD3 in the circumventricular organ in the brain increases blood pressure in the basal state and after Ang II infusion, in part by modulating sympathetic outflow. 35 Intriguingly, Atox1 expression is observed in several regions of brain, including the choroid plexus, which belongs to the circumventricular organ, where ATP7A is also expressed. 36 Thus, it is conceivable that Atox1 may be involved in the regulation of blood pressure, either by regulation of SOD3 in the circumventricular organ or by other secretory copper enzymes in the brain. Atox1 is also expressed in the kidney, including glomeruli in both the juxtramedullary and cortical nephrons and medulla associated with the loops of Henle, 37 which regulates oxidative stress-dependent hypertension. 38 In particular, O 2 ·Ϫ production in the brain is required for the genesis of hypertension. 35, 39 In the current study, we used a noninvasive tail-cuff method to measure blood pressure. However, it does not give the information, such as 24-hour blood pressure and blood pressure variability. Thus, Atox1-SOD3-mediated regulation of Ang II-induced hypertension should be further confirmed using a telemetry system. Furthermore, investigating the role of Atox1 in other oxidative stress-dependent pathophysiologies, such as diabetes mellitus, obesity, and atherosclerosis, in which blood pressure is not consistently increased, 38 is the subject of future studies.
Perspectives
The present study provides compelling evidence that Atox1 plays an important role in regulating vascular function and hypertension induced by Ang II in vivo by decreasing Figure 9 . Proposed model for protective role of antioxidant 1 (Atox1) in angiotensin II (Ang II)-induced hypertension through regulating superoxide dismutase (SOD) 3 expression and activity. Atox1 plays an important role in Ang II-induced transcription and activity of SOD3 by increasing Atox1 binding to the Atox1 response element in the SOD3 promoter, as well as to copper transporter ATP7A protein, required for copper delivery to SOD3 for enhancing its specific activity. As its consequence, Atox1 contributes to the decrease in extracellular superoxide (O 2 ·Ϫ ) levels in the vessel wall, thereby increasing available NO to preserve endothelial function and reduce blood pressure. TGN indicates trans-Golgi network.
extracellular O 2
·Ϫ and increasing bioavailability of NO through copper chaperone and transcription factor function for SOD3 in blood vessels ( Figure 9 ). Atox1 is also involved in regulating copper homeostasis during Ang II-induced hypertension. Our findings provide novel insight into Atox1 as a potential therapeutic target for the treatment of hypertension and various other oxidative stress-dependent cardiovascular diseases. Figure S1: Body weight, the weight of various organs (heart, kidney, Lung, and brain) in Atox1 -/-and WT mice. The results are presented as mean ± SE from three separate experiments. NS, not significant Figure S2 : Total SOD activity in aortas of WT (C57Bl/6, white bars) and Atox1 -/-(black bars) mice. Mice were treated as in Figure 1 . SOD activity assay was performed as in Figure 2 and the results are presented as mean ± SE from three separate experiments. NS, not significant vs either untreated WT or untreated Atox1 -/-mice. 
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